Kristian Pietras

Lund University is advertising tenure-track Assistant Professor positions in immunotherapy , immuno-oncology , and cancer immunotherapy within the Programme for Global Excellence in Lund, Sweden. The post spans several closely related research directions: Immuno-Oncology & Immune Cell Engineering (Faculty of Medicine), Immunotechnology – Cancer Immunotherapy (Faculty of Engineering), and Experimental Cancer Immunotherapy (Translational Cancer Research). The research themes include immune cell engineering, cancer immunology, translational cancer research, and experimental immuno-oncology approaches. Applicants are expected to hold a PhD and/or MD and to have a strong background in immuno-oncology, immunotherapy, or a related field. The post also emphasizes research excellence and independence . The announcement is aimed at outstanding researchers with interest in cancer immunotherapy. This is a full-time tenure-track academic appointment. The post mentions an attractive start-up package , but does not describe a scholarship, tuition waiver, or student stipend. Deadlines listed in the post are: 26 May 2026 for Immunotechnology, 10 June 2026 for Experimental Cancer Immunotherapy, and 30 June 2026 for Immuno-Oncology & Immune Cell Engineering. The latest deadline is used here for the overall post. Contacts named in the post include Sara Ek , Kristian Pietras , and Filipe Pereira . The application link provided in the post points to Lund University’s Varbi recruitment portal.

Lund University and LUCC (Lund University Cancer Centre) are recruiting a tenure-track Assistant Professor in Experimental Cancer Immunotherapy within the Programme for Global Excellence . The position is based at the Faculty of Medicine and is embedded in the CREATE Health translational cancer research environment and the L2CancerBridge programme. This opportunity is aimed at outstanding early-career researchers with a strong background in immuno-oncology , immunotherapy , experimental cancer therapy , and the tumour microenvironment . The research emphasis includes antibody-based immunotherapies , therapeutic targeting of paracrine communication in the tumour microenvironment, pre-clinical validation in advanced mouse models of cancer, and translational work that can move experimental therapies toward clinical entry. Applicants are encouraged to integrate single-cell and spatial omics approaches and collaborate with experimental and computational groups at Lund University. The appointment is for an assistant professor (associate senior lecturer) track with a 5-year development period and a clear path toward promotion to a tenured senior lecturer position. The post includes an attractive start-up package for staff and running costs, plus access to strong research infrastructures such as Lund University Cancer Centre, SciLifeLab antibody networks, LU-ATMP Centre, spatial biology, and flow cytometry platforms. Eligibility highlights include a doctoral degree or equivalent expertise in a relevant field, preferably a PhD awarded within the last 7 years, strong publication record, relevant experience outside Sweden, documented teaching competence, excellent English, motivation to learn Swedish, leadership ability, and the capacity to develop an independent, innovative research plan. The research plan should be 1,000–1,500 words and demonstrate how the project complements ongoing immuno-oncology and tumour microenvironment research at Lund. The application deadline is 10 June 2026 . Apply via the Lund University Varbi portal using the job link provided in the post.

Lund University in Sweden is recruiting three tenure-track Assistant Professors as part of its Programme for Global Excellence to strengthen research in immunotherapy and immuno-oncology . The openings span three closely related areas: Immunotechnology with a focus on cancer immunotherapy , Immuno-Oncology and Immune Cell Engineering , and Experimental Cancer Immunotherapy . The posts are based at Lund University units including the Department of Immunotechnology, the Division of Immuno-Oncology, and the Division of Translational Cancer Research. These are tenure-track faculty positions with a clear path to promotion and an attractive start-up package. The post is aimed at outstanding researchers who can build an internationally competitive programme at the interface of immune engineering , mechanistic discovery , and clinical translation . Eligibility highlights vary slightly by position, but candidates are expected to hold a PhD ; one position accepts PhD and/or MD . A strong background in the relevant research area is required, especially in cancer immunotherapy, immuno-oncology, immunotechnology, or immune cell engineering. Deadlines shown in the post are 26 May 2026 for Immunotechnology, 30 June 2026 for Immuno-Oncology and Immune Cell Engineering, and 10 June 2026 for Experimental Cancer Immunotherapy. Application links are provided via Lund University’s Varbi portal. Contact persons listed in the post include Professor Sara Ek , Professor Filipe Pereira , and Professor Kristian Pietras .